Assessment of thickened endometrium in tamoxifen therapy

Korkmazer, Engin; Solak, Neşe; Tokgöz, Vehbi Yavuz

doi:10.4274/tjod.82621

Cited by 7 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other risk variables, such as body mass index, length of treatment, and prior estrogen replacement therapy to avoid endometrial cancer while taking tamoxifen, were also considered. [3,4] Tamoxifen use for more than five years has been linked to an increased chance of endometrial cancer in previous research. The ATLAS study found that taking tamoxifen for more than five years decreased the chance of breast cancer recurrence but raised the risk of endometrial cancer.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Tamoxifen-associated Endometrial Cancer after Treatment in Young Premenopausal Women with Breast Cancer: A Case Report

Hermansyah,

Anas,

Yaznil

et al. 2024

Acta Inform Med

View full text Add to dashboard Cite

Background: Tamoxifen has been successfully administered as adjunctive therapy for breast cancer. However, the effect of tamoxifen as an estrogen agonist and antagonist can cause pathological changes in the uterus. The agonist effect may stimulate endometrial proliferation leading to endometrial polyps, hyperplasia, and, rarely, endometrial cancer. Objective: We present the case of tamoxifen-treated breast cancer case to better understand one of the most serious consequences, endometrial cancer. Case presentation: A 37-year-old woman came to our centre with complaints of abnormal vaginal bleeding. She has diagnosed with grade I infiltrative ductal carcinoma in 2018, with primary complaints of right breast mass and axillary lymphadenopathy. During this period, adjuvant chemotherapy was given tamoxifen 20 mg once daily. There were no complaints or relapses at a six-month follow-up over three years. In the fourth year, the patient complained of vaginal bleeding. A vaginal biopsy was performed, and the results showed low-grade endometrioid-type endometrial carcinoma. Total hysterectomy and bilateral salpingo-oophorectomy were performed with the resultant mass of up to half of the myometrial lining with metastatic negative parallax lymph nodes. Conclusion: Following tamoxifen therapy, endometrial cancer is more likely to occur in patients. Patients who experience irregular vaginal hemorrhage should have hysteroscopy or uterine ultrasound performed, and if the cause is unknown, a biopsy should be performed.

show abstract

Section: Discussionmentioning

confidence: 97%

“…[1,2] There are no recommendations that suggest gynecological testing for endometrial cancer in premenopausal women taking tamoxifen. [3,4] In this article, we will look at a tamoxifen-treated breast cancer case to better understand one of the most serious consequences, endometrial cancer.…”

Section: Introductionmentioning

confidence: 99%

Tamoxifen-associated Endometrial Cancer after Treatment in Young Premenopausal Women with Breast Cancer: A Case Report

Hermansyah,

Anas,

Yaznil

et al. 2024

Acta Inform Med

View full text Add to dashboard Cite

show abstract

“…Tamoxifen, for instance, though osteoprotective like estrogen (1,2), is reported to increase the uterine weight, endometrial cancer, stroke, and pulmonary embolism (3). A drug that has protective effects in estrogen-dependent tissues and prevents its deleterious effects would serve as an ideal SERM (4).…”

Section: Introductionmentioning

confidence: 99%

“…Tamoxifen and raloxifen are the most commonly used SERMs in treating breast cancer, which is often observed to exert side effects in hormone dependent-tissues. Tamoxifen, for instance, though osteoprotective like estrogen ( 1 , 2 ), is reported to increase the uterine weight, endometrial cancer, stroke, and pulmonary embolism ( 3 ). A drug that has protective effects in estrogen-dependent tissues and prevents its deleterious effects would serve as an ideal SERM ( 4 ).…”

Section: Introductionmentioning

confidence: 99%

Urolithins: The Colon Microbiota Metabolites as Endocrine Modulators: Prospects and Perspectives

et al. 2022

View full text Add to dashboard Cite

Selective estrogen receptor modulators (SERMs) have been used in hormone related disorders, and their role in clinical medicine is evolving. Tamoxifen and raloxifen are the most commonly used synthetic SERMs, and their long-term use are known to create side effects. Hence, efforts have been directed to identify molecules which could retain the beneficial effects of estrogen, at the same time produce minimal side effects. Urolithins, the products of colon microbiota from ellagitannin rich foodstuff, have immense health benefits and have been demonstrated to bind to estrogen receptors. This class of compounds holds promise as therapeutic and nutritional supplement in cardiovascular disorders, osteoporosis, muscle health, neurological disorders, and cancers of breast, endometrium, and prostate, or, in essence, most of the hormone/endocrine-dependent diseases. One of our findings from the past decade of research on SERMs and estrogen modulators, showed that pomegranate, one of the indirect but major sources of urolithins, can act as SERM. The prospect of urolithins to act as agonist, antagonist, or SERM will depend on its structure; the estrogen receptor conformational change, availability and abundance of co-activators/co-repressors in the target tissues, and also the presence of other estrogen receptor ligands. Given that, urolithins need to be carefully studied for its SERM activity considering the pleotropic action of estrogen receptors and its numerous roles in physiological systems. In this review, we unveil the possibility of urolithins as a potent SERM, which we are currently investigating, in the hormone dependent tissues.

show abstract

“…It is very important and vital to diagnose endometrial cancer before cardinal symptoms [especially postmenopausal bleeding] begin. Transvaginal ultrasonography [TVUS], which is used as part of a gynecological examination to view endometrial pathologies helps detect endometrial cancer and provides important information in the differential diagnosis of other endometrial pathologies in symptomatic postmenopausal patients [1,2]. Although the availability of TVUS as a screening method for endometrial or ovarian cancer is limited, TVUS is performed during routine gynecological examinations in asymptomatic postmenopausal women [3,4].…”

Section: Introductionmentioning

confidence: 99%

False Endometrial Thickening in Postmenopausal Patients Using Anticoagulants or Antiplatelets Agents

Ata

Kulhan

2021

Aegean J Obstet Gynecol

View full text Add to dashboard Cite

Objective There is no report that anticoagulant or antiplatelet use may lead to abnormal endometrial sonographic findings. This retrospective study reports our first results associated with endometrial sampling in asymptomatic postmenopausal women using anticoagulants or antiplatelet. Materials methods A total of 268 postmenopausal patients who applied to our gynecology outpatient clinic for any reasons except postmenopausal bleeding were included in the study. Patients were divided into three groups according to using drug status: first healty control group [HCG], second anticoagulants agents group [ACG], and third antiplatelet agents group [APG]. The effects of anticoagulant and antiplatelet agents on endometrial thickness were compared with histopathological findings. Results The mean endometrial thickness was significantly greater in group ACG [5.2 mm] and APG [4.1 m] than in group HCG [3.3 mm]. No significant differences were found in the mean endometrial thickness between groups HCG and APG. However, it is noteworthy that the average endomeric thickness in the ACG group is more than the other two groups and this is statistically significant [p < 0.05]. Conclusion If the thickness of the endometrium was > 4 mm. endometrial sampling may be recommended in in asymptomatic postmenopausal women using anticoagulants or antiplatelet agents.

show abstract

Assessment of thickened endometrium in tamoxifen therapy

Cited by 7 publications

References 13 publications

Tamoxifen-associated Endometrial Cancer after Treatment in Young Premenopausal Women with Breast Cancer: A Case Report

Tamoxifen-associated Endometrial Cancer after Treatment in Young Premenopausal Women with Breast Cancer: A Case Report

Urolithins: The Colon Microbiota Metabolites as Endocrine Modulators: Prospects and Perspectives

False Endometrial Thickening in Postmenopausal Patients Using Anticoagulants or Antiplatelets Agents

Contact Info

Product

Resources

About